RoslinCT and the Revolutionary CRISPR-Based Gene Therapy CASGEVY™
RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has achieved a groundbreaking milestone in the field of medical science. Building on its legacy since the cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has now been entrusted with the manufacturing of the first-ever U.S. Food and […]
RoslinCT Unveils CRISPR: A Medical Revolution Begins
RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has announced a significant advancement in the field of medical science. They will be manufacturing the world’s first CRISPR-based therapy, exa-cel, for Vertex Pharmaceuticals Inc. This development follows an extensive collaboration between the two entities. Key Highlights: About RoslinCT: RoslinCT has a […]
RoslinCT and Lykan Bioscience: The Dynamic Duo Redefining the Future of Cell and Gene Therapy
RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, have announced their integration to form a unified business that will operate under the RoslinCT brand. This integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell […]
RoslinCT and Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO
EDINBURGH, UK AND HOPKINTON, MA, 4 August 2022 – RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience (‘Lykan’), an innovative CDMO focused on cell-based therapies, today announce that they have entered into a business combination agreement to form a global leading innovative […]